‘Hard To Lose’ Mutations In Tumors May Predict Response To Immunotherapy

‘Hard To Lose’ Mutations In Tumors May Predict Response To Immunotherapy

Cancer experts have tried, sometimes unsuccessfully, to use the total number of mutations in a tumor, called the tumor mutation burden (TMB), to predict a patient’s response to immunotherapy. Now, Johns Hopkins investigators have found that a subset of mutations within the overall TMB, termed “persistent mutations,” are less likely to be edited out as cancer evolves, rendering tumors more likely to respond to immunotherapy. Read more here.

Recent Posts
Study Shows Patient/Clinician Identity Differences Are Factor in Cancer Care Study Finds Diverse Differences in Microbes in Breast Tumors From Women of Different Races Nutrition Fact, Fiction or Somewhere in Between? What are dense breasts? New Blood Test for Cancer The Best Way to Take A Pill, According to Science 8 Ways to Lose Belly Fat and Live a Healthier Life Sunglasses Are More Than Just a Fashion Accessory Liquid Biopsy Detects DNA Markers in Advanced Breast Cancer Within Five Hours